Mounjaro Overtakes Keytruda as World's Top Drug

The Drug That Just Changed the Global Leaderboard

For decades, cancer drugs and cholesterol medications dominated the list of the world's best-selling pharmaceuticals. That list just changed in a significant way.

Eli Lilly's Mounjaro (tirzepatide) has overtaken Merck's Keytruda, a leading cancer immunotherapy, to become the top-selling drug in the world by revenue. This is not a small reshuffling. Keytruda had held a dominant position for years and represented the gold standard of oncology treatment. Being surpassed by a metabolic disease drug reflects just how profoundly GLP-1 medications have reshaped the pharmaceutical landscape.

For patients who are currently taking or researching tirzepatide, this milestone is worth understanding. It tells you something important about the medication you are considering, the company behind it, and what demand at this scale means for your access and costs.

What Mounjaro Actually Is (And What Makes It Different)

Mounjaro is a dual GIP and GLP-1 receptor agonist (a medication that activates two hormone pathways in the body that regulate blood sugar and appetite). Most GLP-1 medications, including Ozempic and Wegovy, activate only the GLP-1 pathway. Mounjaro activates both GIP and GLP-1 receptors, which is why clinical trials have shown notably strong results in weight loss and blood sugar control.

Mounjaro is FDA-approved for type 2 diabetes management. Its sister medication, Zepbound, contains the same active ingredient (tirzepatide) and is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related condition.

Why Tirzepatide Generates This Much Revenue

The short answer is that it works, and millions of people need it. Clinical trials showed that tirzepatide helped participants lose up to 22.5% of their body weight over 72 weeks at the highest dose. That level of efficacy drove demand unlike anything the weight loss category had seen before.

Combine strong clinical results with a massive patient population (over 100 million adults in the United States have obesity), and you get the kind of commercial performance that can topple even the most dominant drugs on the market.

What This Sales Milestone Tells Patients

You might be wondering why a drug company's revenue ranking matters to you as a patient. Here are a few reasons it genuinely does.

It Confirms Tirzepatide Is Mainstream Medicine

When a weight loss medication becomes the world's top-selling drug, it crosses a threshold. Insurers, policymakers, and healthcare systems can no longer treat obesity pharmacotherapy as a niche or optional category. This visibility tends to move coverage conversations forward, even if slowly.

It Signals Lilly's Financial Capacity to Expand

One of the biggest complaints from Mounjaro and Zepbound patients over the past two years has been supply shortages. Eli Lilly has been aggressively investing in manufacturing capacity, including billions of dollars in new production facilities in the United States and abroad. Higher revenues mean more capital available to close the gap between supply and demand.

It Reflects Real Patient Outcomes, Not Just Hype

Drugs do not reach number one by marketing alone. Keytruda earned its position because oncologists saw it save lives. Mounjaro earned its position because patients and physicians saw meaningful, sustained results in both blood sugar control and weight reduction. The sales figure is, in part, a reflection of clinical effectiveness at scale.

The Flip Side: What High Demand Means for Access and Cost

There is no way to talk about Mounjaro's success without addressing the access challenges that come with it. High demand has created real friction for patients.

Supply and Shortage Concerns

The FDA removed tirzepatide from its official shortage list in late 2024, which means Eli Lilly demonstrated it could meet demand through licensed channels. However, individual patients may still experience delays or pharmacy-level availability issues depending on their location and dosage. If you are starting or continuing tirzepatide, building a relationship with a consistent pharmacy and planning your refills in advance can prevent interruptions.

The Cost Reality

Mounjaro's list price in the United States is approximately $1,000 to $1,100 per month without insurance. That is a significant barrier for many patients, even as the medication dominates global sales charts.

Here is a realistic breakdown of what patients typically pay through different access pathways:

Coverage for obesity (as opposed to type 2 diabetes) remains one of the most frustrating access gaps in the GLP-1 space. Many insurance plans still exclude weight management medications, which means patients with Zepbound prescriptions often face higher out-of-pocket costs than those with Mounjaro for diabetes.

How Mounjaro Compares to Other GLP-1 Medications at This Scale

Mounjaro is not the only option in the GLP-1 and GIP category, but it is currently the most commercially dominant. Here is how it fits alongside the other major medications in this class.

Tirzepatide's dual-action mechanism is frequently cited as a reason for its stronger average weight loss results in head-to-head comparisons with semaglutide. That said, individual responses vary, and the "best" medication is the one that works for your specific health profile, tolerability, and coverage situation. A physician or qualified prescriber should guide that decision.

What Eli Lilly's Success Means for the Future of GLP-1 Treatment

Eli Lilly's record revenues are being reinvested in a few areas that could directly benefit patients over the next several years.

Manufacturing Expansion

Lilly has committed tens of billions of dollars to new manufacturing sites, including facilities in Indiana, North Carolina, and Ireland. More production capacity should reduce the supply volatility that has frustrated patients and providers alike.

Pipeline Medications

With strong cash flow, Lilly is advancing next-generation weight loss and metabolic medications in its pipeline. These include oral tirzepatide formulations and longer-acting injectable options that could eventually provide patients with more flexible treatment choices.

Competitive Pressure Driving Innovation

Mounjaro's success has accelerated development across the entire industry. Competitors including Novo Nordisk, Pfizer, and Amgen are all working to bring new obesity and metabolic medications to market. Competition typically benefits patients through pricing pressure and expanded options over time.

Practical Guidance for Patients Considering Mounjaro

If you are thinking about tirzepatide for weight management or diabetes control, here is what you should focus on right now.

Talk to Your Doctor About the Right Indication

Whether you are prescribed Mounjaro or Zepbound can affect your insurance coverage significantly. Mounjaro is the diabetes-indicated version and Zepbound is the obesity-indicated version, even though they contain the same molecule. Your diagnosis, medical history, and insurer's formulary will influence which version makes sense for you.

Ask Your Provider These Specific Questions

• Based on my health profile and diagnosis, should I be prescribed Mounjaro for type 2 diabetes or Zepbound for weight management, and how does that choice affect what my insurance will cover and what I will pay out of pocket?
• What realistic weight loss should I expect on tirzepatide given my starting weight, metabolic history, and any other conditions I am managing, and how will we measure whether the medication is working well enough to continue?
• Are there any medications I currently take that could interact with tirzepatide or affect how well it works, and should we review my full medication list before starting?
• What does the titration schedule look like, and how will we handle side effects if they become significant during dose escalation, including at what point we would consider adjusting the pace?
• Am I eligible for the Eli Lilly savings card, and if not, what other manufacturer assistance programs, insurance appeal pathways, or telehealth pricing options should I explore before paying full list price?
• What is your recommended protein intake and resistance exercise approach alongside this medication to protect my lean muscle mass, and should I be working with a dietitian to manage nutrition during treatment?

Explore All Cost-Saving Options Before You Fill

Many patients pay far more than necessary because they do not know about available savings programs. Before you fill your first prescription, check the GLP-1 Coupons page on GLP-1.com to see current savings options for tirzepatide and other medications in this class.

Comparing Best Providers for telehealth prescriptions can also uncover more affordable pathways to getting started, particularly if you do not have insurance coverage for weight management medications.